AB198684

Anti-SIGLEC15 antibody

Name: Anti-SIGLEC15 antibody (ab198684) | Abcam
Brand: Abcam Limited
SKU: AB198684

Be the first to review this product! Submit a review

(12 Publications)

Rabbit Polyclonal SIGLEC15 antibody. Suitable for IHC-P and reacts with Human samples. Cited in 12 publications. Immunogen corresponding to Synthetic Peptide within Human SIGLEC15.

View Alternative Names

CD33L3, SIGLEC15, Sialic acid-binding Ig-like lectin 15, Siglec-15, CD33 antigen-like 3

2 Images

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-SIGLEC15 antibody (AB198684)

IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-SIGLEC15 antibody (AB198684)

Immunohistochemical analysis of paraffin-embedded Human prostate cancer tissue labeling SIGLEC15 with ab198684 at 1/35 dilution.

IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-SIGLEC15 antibody (AB198684)

Immunohistochemical analysis of paraffin-embedded Human tonsil cancer tissue labeling SIGLEC15 with ab198684 at 1/35 dilution.

Key facts

Host species

Rabbit

Clonality

Polyclonal

Isotype

IgG

Carrier free

Reacts with

Human

Applications

IHC-P

applications

Immunogen

Synthetic Peptide within Human SIGLEC15. The exact immunogen used to generate this antibody is proprietary information.

Q6ZMC9

style

left-column

style

left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/25 - 1/100", "IHCP-species-notes": "<p></p>" }, "Rat": { "IHCP-species-checked": "predicted", "IHCP-species-dilution-info": "", "IHCP-species-notes": "" } } }

style

left-column

style

left-column

Properties and storage information

Form

Liquid

Purification technique

Affinity purification Immunogen

Storage buffer

pH: 7.4 Preservative: 0.05% Sodium azide Constituents: PBS, 50% Glycerol (glycerin, glycerine)

Shipped at conditions

Blue Ice

Appropriate short-term storage duration

1-2 weeks

Appropriate short-term storage conditions

+4°C

Appropriate long-term storage conditions

-20°C

Aliquoting information

Upon delivery aliquot

Storage information

Avoid freeze / thaw cycle

style

left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

SIGLEC15 also known as sialic acid-binding Ig-like lectin 15 is a transmembrane protein with an approximate mass of 50 kDa. This protein is a member of the SIGLEC family that binds sialic acids on glycoproteins and glycolipids. SIGLEC15 is highly expressed in cells of the osteoclast lineage and some other immune cells. It typically functions as a receptor that can modulate immune cell interactions and signaling by recognizing and binding to sialylated glycans on other cells.

Biological function summary

SIGLEC15 plays roles in modulating the immune system and bone remodeling processes. It is not usually part of a larger complex but primarily acts as a cell surface receptor. SIGLEC15 helps regulate osteoclast differentiation and activity which are important for maintaining bone homeostasis. It modulates immune responses by interacting with other immune cells which can dampen or activate immune signaling pathways based on the cellular context.

Pathways

SIGLEC15 influences both immune signaling and bone metabolism pathways. It is involved in the RANKL-mediated osteoclastogenesis pathway which is critical for the formation and activation of osteoclasts. Within these pathways SIGLEC15 can relate to other proteins like RANK and RANKL that are essential in osteoclast development and function. Through its expression and interactions SIGLEC15 plays key roles in the regulation of immune and skeletal systems.

SIGLEC15 plays a significant role in osteoporosis and certain cancers. In osteoporosis SIGLEC15 expression in osteoclasts is elevated which can lead to increased bone resorption and weakened bones. In cancer its expression on tumor-associated macrophages and other cells can help tumors evade immune surveillance. In such conditions proteins like RANK RANKL and other immune checkpoint proteins may also be implicated providing potential targets for therapeutic intervention alongside SIGLEC15.

style

left-column

style

left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Visit the General protocols
Visit the Troubleshooting

style

left-column

Target data

Binds sialylated glycoproteins.

See full target information SIGLEC15

style

left-column

Publications (12)

Recent publications for all applications. Explore the full list and refine your search

Bioengineering & translational medicine 9:e10651 PubMed39553435

2024

Siglec15/TGF-β bispecific antibody mediates synergistic anti-tumor response against 4T1 triple negative breast cancer in mice.

Applications

Unspecified application

Species

Unspecified reactive species

Limei Shen,Alison M Schaefer,Karthik Tiruthani,Whitney Wolf,Samuel K Lai

The Journal of cell biology 223: PubMed39352498

2024

Organization of a cytoskeletal superstructure in the apical domain of intestinal tuft cells.

Applications

Unspecified application

Species

Unspecified reactive species

Jennifer B Silverman,Evan E Krystofiak,Leah R Caplan,Ken S Lau,Matthew J Tyska

Histology and histopathology 40:571-584 PubMed39301699

2024

Expression feature and prognostic function of a novel immune checkpoint Siglec-15 in human colorectal cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Guodong Liang,Linyun Zhou,Yang Fan,Run Ding,Junrong Yang,Li Xu,Yidan Zhu,Wen Huang

The clinical respiratory journal 18:e13772 PubMed38725348

2024

The expression characteristic and prognostic role of Siglec-15 in lung adenocarcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

Haijun Sun,Qilong Du,Yuyu Xu,Cheng Rao,Li Xu,Junrong Yang,Yuan Mao,Lin Wang

Frontiers in immunology 14:1065062 PubMed37325664

2023

Siglec15 is a prognostic indicator and a potential tumor-related macrophage regulator that is involved in the suppressive immunomicroenvironment in gliomas.

Applications

Unspecified application

Species

Unspecified reactive species

Jinchao Wang,Linzong Xu,Qian Ding,Xiaoru Li,Kai Wang,Shangchen Xu,Bin Liu

Frontiers in endocrinology 13:1055826 PubMed36506053

2022

Immunosuppressive environment in response to androgen deprivation treatment in prostate cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Caipeng Qin,Jing Wang,Yiqing Du,Tao Xu

Current oncology (Toronto, Ont.) 29:7655-7671 PubMed36290882

2022

Siglec-15 as a New Perspective Therapy Target in Human Giant Cell Tumor of Bone.

Applications

Unspecified application

Species

Unspecified reactive species

Mengke Fan,Guochuan Zhang,Mingfang Xie,Xinbo Liu,Qi Zhang,Ling Wang

Scientific reports 12:10401 PubMed35729260

2022

Prognostic value of PD-L1 and Siglec-15 expression in patients with nasopharyngeal carcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

Ju Zhao,Hanshan Yang,Hui Hu,Chao Liu,Min Wei,Yumei Zhao,Yudan Chen,Yongxia Cui,Ping Chen,Kang Xiong,Yun Lu,Hongru Yang,Linglin Yang

The journal of pathology. Clinical research 8:268-278 PubMed35083884

2022

Analysis of a novel immune checkpoint, Siglec-15, in pancreatic ductal adenocarcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

Xianlong Chen,Shengwei Mo,Yue Zhang,Heng Ma,Zhaohui Lu,Shuangni Yu,Jie Chen

Frontiers in oncology 11:710689 PubMed34336699

2021

Siglec-15 Promotes Tumor Progression in Osteosarcoma DUSP1/MAPK Pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Meng-Ke Fan,Guo-Chuan Zhang,Wei Chen,Li-Li Qi,Ming-Fang Xie,Yue-Yao Zhang,Ling Wang,Qi Zhang

View all publications

style

left-column

style

left-column

style

right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.

For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com

Anti-SIGLEC15 antibody

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-SIGLEC15 antibody (AB198684)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-SIGLEC15 antibody (AB198684)

Key facts

Host species

Clonality

Isotype

Carrier free

Reacts with

Applications

Immunogen

Alternative Products

Primary Antibodies

Complementary Products

Secondary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Reactivity data

Properties and storage information

Form

Purification technique

Storage buffer

Shipped at conditions

Appropriate short-term storage duration

Appropriate short-term storage conditions

Appropriate long-term storage conditions

Aliquoting information

Storage information

Supplementary information

Biological function summary

Pathways

Product protocols

Target data

Publications (12)

Product promise